OKYO Pharma Ltd (OKYO) stock
OKYONasdaqBiological Products, (No Diagnostic Substances)
Số liệu tài chính tới năm tài chính 2026, năm kết thúc ngày Mar 31, 2026Last filing: 20-F on Jul 20, 2026Score 1/30
$1.10−0.00 (-0.45%)
Close on Nov 18, 2026Market cap $57.73MP/E –Yield –
OKYO Pharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2026 it was $1.81M, down 19.7% from the year before. The highest annual figure on record is $8.24M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $1.81M | -19.7% |
| FY2025 | Mar 31, 2025 | $2.25M | -72.7% |
| FY2024 | Mar 31, 2024 | $8.24M | +30.1% |
| FY2023 | Mar 31, 2023 | $6.34M | +293.8% |
| FY2022 | Mar 31, 2022 | $1.61M | +362.1% |
| FY2021 | Mar 31, 2021 | $348.35K | -32.8% |
| FY2020 | Mar 31, 2020 | $518.10K | – |
See a number that looks wrong?